BeStock  
Stocks › Biotechnology › CRVS

Corvus Pharmaceuticals CRVS

US equityMarket cap rank #3332Biotechnology
$10.41 −$0.15 (-1.42%)
Pre-market · Oct 8, 8:20 am ET · After hours $10.52 +1.06%
Open$10.25
Prev close$10.56
Day range$10.25 – $10.65
Volume1.16M
Market cap$875.70M
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-16.3x
CheapRich

Near the bottom of its 5-year range · 18th percentile, 5-year average -10.8x

Price / book3.9x
CheapRich

Around its usual level · 54th percentile, 5-year average 6.2x

#4016 of 5317 stocks by PB (1 = cheapest)

P/E over five years

-578x-351x-125x102xOct '21Apr '24Oct '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$16.41
Price vs. fair value-36.6%Trading below the estimate
Star rating★★★★☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 3.89 – 6.20 54% (pricier than usual) #4016 of 5317 (1 = cheapest)
PE -16.27 -9.72 -10.80 18% (cheaper than usual) –
PS – – 0.00 – –

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Morningstar view

Star rating★★★★
Fair value estimate$16.41
Economic moatNone
UncertaintyVery High

Discussion

No comments yet — be the first to weigh in on CRVS.

Leave a comment

Scroll to Top